2023
Late Mortality After COVID-19 Infection Among US Veterans vs Risk-Matched Comparators
Iwashyna T, Seelye S, Berkowitz T, Pura J, Bohnert A, Bowling C, Boyko E, Hynes D, Ioannou G, Maciejewski M, O’Hare A, Viglianti E, Womer J, Prescott H, Smith V, Admon A, Akgun K, Anderson S, Aslan M, Au D, Backus L, Bajema K, Baraff A, Batten L, Berkowitz T, Bernstein T, Berry Wyatt K, Bogdan J, Bosworth H, Boucher N, Burwick N, Cabrales A, Cano J, Chai W, Chen J, Cheung K, Crothers K, Curtis J, Davis M, Del Monico E, Dobalian A, Doll J, Dominitz J, Eastment M, Fan V, Ferguson J, Floyd B, Fox A, Goetz M, Govier D, Green P, Hastings S, Hauschildt K, Hawkins E, Hebert P, Helfand M, Hickok A, Horowitz D, Hough C, Hu E, Ikuta K, Jones B, Jones M, Kamphuis L, Kaufman B, Knight S, Korpak A, Korpela P, Kumbier K, Langa K, Laundry R, Lavin S, Li Y, Linquist J, McCready H, Michel M, Miles A, Milne J, Monahan M, Morelli D, Mutalik P, Naylor J, Neiderhausen M, Newell S, Nugent S, Ong M, Osborne T, Peterson M, Peterson A, Rajeevan N, Reddy A, Rouse M, Rowneki M, Saha S, Saini S, Shah J, Shahoumian T, Shaukat A, Shepherd-Banigan M, Showalter W, Slatore C, Smith N, Smith B, Suri P, Sussman J, Takata Y, Teo A, Thomas E, Thomas L, Tuepker A, Veigulis Z, Vig E, Vranas K, Wang X, Wicks K, Winchell K, Wong E, Woods C, Wysham K, Yan L, Zulman D. Late Mortality After COVID-19 Infection Among US Veterans vs Risk-Matched Comparators. JAMA Internal Medicine 2023, 183: 1111-1119. PMID: 37603339, PMCID: PMC10442778, DOI: 10.1001/jamainternmed.2023.3587.Peer-Reviewed Original ResearchCOVID-19 infectionAdjusted hazard ratioRetrospective cohort studyUninfected comparatorsLate mortalityCohort studyHazard ratioMortality riskCOVID-19Acute COVID-19Excess mortality riskUnadjusted mortality ratesVeterans Affairs hospitalCOVID-19 persistHealth record dataCause mortalityCox regressionUS veteransExcess mortalityDay 180Mortality rateUninfected individualsPrimary analysisDay 91Excess deaths
2021
Prostate Cancer Screening and Incidence among Aging Persons Living with HIV
Leapman MS, Stone K, Wadia R, Park LS, Gibert CL, Goetz MB, Bedimo R, Rodriguez-Barradas M, Shebl F, Justice AC, Brown ST, Crothers K, Sigel KM. Prostate Cancer Screening and Incidence among Aging Persons Living with HIV. Journal Of Urology 2021, 207: 324-332. PMID: 34555924, PMCID: PMC8741750, DOI: 10.1097/ju.0000000000002249.Peer-Reviewed Original ResearchConceptsPSA testingHIV statusProstate cancerProstate biopsyCancer incidenceHuman immunodeficiency virus statusProstate-specific antigen (PSA) testingVeterans Aging Cohort StudyProspective national cohortMultivariable Poisson modelsAging Cohort StudySpecific antigen testingHuman immunodeficiency virusProstate cancer screeningUninfected comparatorsCohort studyIncident cancerAntigen testingImmunodeficiency virusMean ageCancer screeningNational cohortCancer stageVirus statusMultivariable model
2019
Polypharmacy, Hazardous Alcohol and Illicit Substance Use, and Serious Falls Among PLWH and Uninfected Comparators.
Womack JA, Murphy TE, Rentsch CT, Tate JP, Bathulapalli H, Smith AC, Bates J, Jarad S, Gibert CL, Rodriguez-Barradas MC, Tien PC, Yin MT, Gill TM, Friedlaender G, Brandt CA, Justice AC. Polypharmacy, Hazardous Alcohol and Illicit Substance Use, and Serious Falls Among PLWH and Uninfected Comparators. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: 305-313. PMID: 31339866, PMCID: PMC7176040, DOI: 10.1097/qai.0000000000002130.Peer-Reviewed Original ResearchConceptsIllicit substance useHazardous alcoholSerious fallsUninfected comparatorsMedication classesOpioid prescriptionsSubstance useHIV statusMuscle relaxantsRisk factorsVeterans Aging Cohort StudyAging Cohort StudyIllicit substance abuseUnconditional logistic regressionNon-ART medicationsHazardous alcohol useSubstance use/abuseCase-control designKey risk factorsUse/abuseCohort studyMedication countInjury codesDuration of observationBaseline date
2017
Clinically significant mutations in HIV-infected patients with lung adenocarcinoma
Thaler J, Sigel C, Beasley MB, Wisnivesky J, Crothers K, Bauml J, Hysell K, Emu B, Borsu L, Sigel K. Clinically significant mutations in HIV-infected patients with lung adenocarcinoma. British Journal Of Cancer 2017, 117: 1392-1395. PMID: 28934759, PMCID: PMC5672933, DOI: 10.1038/bjc.2017.333.Peer-Reviewed Original ResearchConceptsPrevalence of eGFRHIV statusKRAS mutationsLung adenocarcinomaMutation statusLung adenocarcinoma patientsPresence of KRASUninfected comparatorsOverall survivalAdenocarcinoma patientsTumor EGFRLung cancerMutational testingPatientsMajor causeEGFRPrevalenceGenetic alterationsHIVAdenocarcinomaSignificant mutationsStatusSurvivalMutationsSubjects
2015
Thirty-Day Postoperative Mortality Among Individuals With HIV Infection Receiving Antiretroviral Therapy and Procedure-Matched, Uninfected Comparators
King JT, Perkal MF, Rosenthal RA, Gordon AJ, Crystal S, Rodriguez-Barradas MC, Butt AA, Gibert CL, Rimland D, Simberkoff MS, Justice AC. Thirty-Day Postoperative Mortality Among Individuals With HIV Infection Receiving Antiretroviral Therapy and Procedure-Matched, Uninfected Comparators. JAMA Surgery 2015, 150: 343-351. PMID: 25714794, PMCID: PMC5015449, DOI: 10.1001/jamasurg.2014.2257.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionCD4 cell countImmunodeficiency virus infectionAntiretroviral therapyPostoperative mortalityHIV infectionHIV-1 RNAIncidence rate ratiosUninfected patientsVirus infectionCell countUninfected comparatorsSurgical outcomesSurgical proceduresCD4 cell count strataCharlson Comorbidity Index scoreCommon inpatient surgical proceduresHIV-1 RNA levelsThirty-day postoperative mortalityUndetectable HIV-1 RNAVeterans Health Administration healthcare systemElectronic medical record dataCombination antiretroviral therapyComorbidity Index scoreCoronary artery bypass
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply